Anti-Hantavirus Andes Glycoprotein 2, monoclonal, mouse
Size: 100 µg
Price: EUR 445.00
Quantity:
Anti-Hantavirus Andes Glycoprotein, monoclonal, mouse
Size: 100 µg
Price: EUR 445.00
Quantity:
Anti-Hantavirus Andes Nucleoprotein, monoclonal, mouse
Size: 100 µg
Price: EUR 445.00
Quantity:
Anti-Hantavirus Andes Strain Glycoprotein 1, monoclonal, mouse
Size: 100 µg
Price: EUR 445.00
Quantity:
Anti-Hantavirus Four Corners (Sin Nombre) Nucleoprotein, monoclonal, mouse
Size: 100 µg
Price: EUR 445.00
Quantity:
Anti-Hantavirus Hantaan strain (HTNV) glycoprotein 1, monoclonal, mouse
Size: 100 µg
Price: EUR 445.00
Quantity:
Anti-Hantavirus Puumula Strain (PUUV) Glycoprotein 1, monoclonal, mouse
Size: 100 µg
Price: EUR 445.00
Quantity:
Anti-Hantavirus Puumula Strain (PUUV) Nucleoprotein, monoclonal, mouse
Size: 100 µg
Price: EUR 445.00
Quantity:
Anti-Hantavirus Seoul Strain Glycoprotein 1, monoclonal, mouse
Size: 100 µg
Price: EUR 445.00
Quantity:
Anti-Helicobacter pylori Cag antigen, monoclonal, mouse
Size: 100 µg
Price: EUR 385.00
Quantity:
Anti-Helicobacter pylori Cag antigen, monoclonal, mouse
Size: 1 mg
Price: EUR 285.00
Quantity:
**Interview with Dr. Emily Thompson, Virologist and Researcher on Hantaviruses**
**Interviewer:** Thank you for joining us today, Dr. Thompson. You recently conducted a study on the prevalence of antibodies against hantaviruses and their implications. Can you summarize your findings for our audience?
**Dr. Thompson:** Absolutely! Our research focused on the two main hantavirus species affecting humans—Andes virus (ANDV) and Sin Nombre virus (SNV). We discovered a significant presence of antibodies in both serum and saliva samples, indicating previous exposure to these viruses. This suggests a wider spread than previously understood, particularly in at-risk populations in South and North America.
**Interviewer:** That’s intriguing. What does the presence of these antibodies imply about disease risk in these populations?
**Dr. Thompson:** The presence of antibodies typically means that a person has been exposed to the virus, and while not everyone develops severe disease, it does signify some level of risk. In areas where hantaviruses are endemic, we see a correlation between exposure and the emergence of serious conditions like hantavirus pulmonary syndrome.
**Interviewer:** Considering these findings, what preventive measures would you recommend for communities at risk?
**Dr. Thompson:** Education is key. Communities need awareness programs about avoiding contact with rodent populations, which are primary carriers of these viruses. Additionally, maintaining clean living environments, proper food storage, and using protective gear when dealing with potential rodent exposure are critical preventive steps.
**Interviewer:** You mentioned the two predominant viruses—ANDV and SNV. Are there any significant differences in infection rates or disease severity between these two?
**Dr. Thompson:** Yes, there are some differences. ANDV is known to cause more severe disease and has a higher mortality rate compared to SNV. This might be due to the fact that ANDV can be spread person-to-person, which is less common with SNV. Each virus requires tailored public health approaches depending on the specific risks they present.
**Interviewer:** Fascinating. Lastly, how can researchers and medical professionals use your findings to improve public health responses to hantavirus outbreaks?
**Dr. Thompson:** Our findings can guide surveillance efforts in at-risk areas, helping to prioritize testing and monitoring strategies. By understanding where these antibodies are prevalent, we can better allocate resources for public health initiatives and develop effective vaccines or treatments in the future.
**Interviewer:** Thank you, Dr. Thompson, for sharing your insights on hantaviruses and the importance of these findings for public health.
**Dr. Thompson:** My pleasure! It’s crucial we continue raising awareness and understanding of these viruses to protect our communities.
